Short Interest in 20/20 Biolabs Inc (NASDAQ:AIDX) Drops By 36.0%

20/20 Biolabs Inc (NASDAQ:AIDX – Get Free Report) saw a significant decline in short interest in the month of June. As of June 30th, there was short interest totaling 186,863 shares, a decline of 36.0% from the June 15th total of 291,990 shares. Currently, 1.5% of the shares of the company are short sold. Based on an average daily trading volume, of 424,508 shares, the days-to-cover ratio is presently 0.4 days.

Analysts Set New Price Targets

AIDX has been the topic of several recent research reports. Weiss Ratings began coverage on shares of 20/20 Biolabs in a research report on Thursday, May 14th. They issued a “sell (e-)” rating on the stock. Maxim Group began coverage on shares of 20/20 Biolabs in a research report on Monday, May 11th. They set a “buy” rating and a $5.00 price objective for the company. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $5.00.

Get 20/20 Biolabs alerts:

Get Our Latest Stock Report on AIDX

20/20 Biolabs Stock Down 0.3%

Shares of NASDAQ AIDX traded down $0.00 during trading on Friday, hitting $0.53. The company had a trading volume of 4,640 shares, compared to its average volume of 613,571. The company has a 50 day simple moving average of $0.85. 20/20 Biolabs has a 12 month low of $0.51 and a 12 month high of $50.00. The company has a market capitalization of $6.47 million and a price-to-earnings ratio of -1.89.

20/20 Biolabs (NASDAQ:AIDX – Get Free Report) last posted its quarterly earnings data on Wednesday, May 20th. The company reported ($0.28) earnings per share for the quarter. The firm had revenue of $0.35 million during the quarter.

20/20 Biolabs Company Profile

(Get Free Report)

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.

Featured Stories

• Five stocks we like better than 20/20 Biolabs
• 3 Picks-and-Shovels Stocks Powering the Humanoid Robotics Buildout
• J.B. Hunt Stock Could Reach $340 as Trucking Capacity Shrinks
• The AI Data Center Boom Is Bigger Than One Stock—These ETFs Spread the Bet
• Palantir’s Wild Ride: Inside the Stock Wall Street Can’t Agree On

Receive News & Ratings for 20/20 Biolabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 20/20 Biolabs and related companies with MarketBeat.com's FREE daily email newsletter.